Danaher Corporation (DHR)

NYSE: DHR · USD

$234

+1.67 (+0.7%)· Recorded snapshot

İngilizce yedekTR

Çeviri yapılırken İngilizce kaynak gösteriliyor

Bu rapor henüz çevrilmedi. Çeviri kuyruğu yetiştiğinde birkaç dakika sonra sayfayı yenileyin.

StockMarketAgent Research · Analyzed 2026-09-25

Our latest published analysis: DHR rated Reduce

Danaher Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$187 / share

Potential value

$206 / share

Upside to FV

-16.7%

from $234

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$157.3B
Revenue (ttm)	25.6B
Net income (ttm)	4.3B
EPS (ttm)	$6.10
Shares out	703.5M
P/E (trailing)	38.3x
P/E (forward)	23.8x
Dividend	$1.60 (0.68%)
Volume	2,725,890
Beta	0.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 25.6B
Net income (ttm): 4.3B
EPS (ttm): $6.10
P/E (trailing): 38.3x
P/E (forward): 23.8x
Market cap: $157.3B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$24.80B	$26.64B	$23.89B	$23.88B	$24.57B	-0.2%
Gross profit	$15.24B	$16.19B	$14.03B	$14.21B	$14.52B	-1.2%
Operating income	$6.38B	$7.54B	$5.20B	$4.86B	$4.69B	-7.4%
Net income	$6.43B	$7.21B	$4.76B	$3.90B	$3.61B	-13.4%
EPS (diluted)	$8.61	$9.66	$6.38	$5.29	$5.05	-12.5%
EBITDA	$10.01B	$9.49B	$5.20B	$7.28B	$6.95B	-8.7%
R&D	$1.50B	$1.53B	$1.50B	$1.58B	$1.60B	+1.6%
SG&A	$6.82B	$7.12B	$7.33B	$7.76B	$8.24B	+4.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	Sat
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	Sat
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	Güçlü Al
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Sat
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Azalt
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Azalt

Base and Bull scenarios

Base60%

Price target

$186.58

-16.7% from spot

Consolidated core revenue expands at 3%-4% in FY2026 and reaccelerates to 8.0% in FY2027 as customer batch manufacturing schedules normalize and deferred chromatography resin shipments deliver,. Operating margins progress from 19.09% in FY2025 to 26.5% in FY2026 and reach 28.5% over the forecast horizon,. Free cash flow conversion remains above 100%, funding debt service and regular share repurchases.

Core revenue growth of 3%-4% in FY2026 and 8.0% in FY2027
Operating margin expands from 19.09% to 26.5% in FY2026, reaching 28.5% by FY2034
Respiratory revenue stabilizes at approximately $1.6B
Cost of equity of 8.54% and terminal growth rate of 3.0%

Bull20%

Price target

$206.33

-7.8% from spot

Rapid absorption of bioprocessing inventory leads to accelerated commercial batch manufacturing and new greenfield quoting. Specialty diagnostics maintain high single-digit momentum driven by DxI 9000 and Cepheid non-respiratory assays, while China hospital procurement rebounds. Operating margins expand ahead of schedule, driving strong double-digit earnings growth.

Bioprocessing organic revenue growth accelerates into double digits (>10%)
Consolidated operating margins reach peak levels on strong consumable volume leverage
China High Growth Markets core growth rebounds to 8%-10%
StatLab and new 510(k) assays exceed accretion expectations

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($186.58). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
7.5%	$207	$212	$217	$224	$231
8.0%	$192	$196	$201	$205	$211
8.5%	$180	$183	$187	$190	$194
9.0%	$170	$172	$175	$178	$181
9.5%	$161	$163	$165	$167	$170

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E23.8

P25 n/aP50 n/aP75 n/a

Trailing P/E39.5

P25 n/aP50 n/aP75 n/a

ROE8.2

P25 n/aP50 n/aP75 n/a

ROIC6.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DHR indicators

Market & fundamental data

Available fields

287

Groups with data

Currency

USD

Showing 287 of 287 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000313616
Company name	Danaher Corporation
Country	United States
Country code	US
CUSIP number	235851102
Earnings date	2026-10-21
Earnings time	bmo
Employees	60,000
Employees change	-3,000
Employees growth	-4.76%
Enterprise value	$186.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-25
First seen	2026-05-09
Fiscal year end	December
Founded	1969
In index	SP500
Industry	Diagnostics & Research
Is primary listing	Yes
Is SPAC	No
ISIN number	US2358511028
Last 10-K release date	2026-02-24
Last earnings date	2026-10-21
Last refreshed	2026-10-28
Last stock split date	2010-06-14
Last stock split type	Forward
Market cap	$164.4B
Market cap category	Large-Cap
Next earnings date	2027-01-27
Options	Yes
Price	$233.66
Price currency	USD
Sector	Healthcare
SIC code	3823
Stock price date	2026-10-28
Symbol	DHR
U.S. state	District of Columbia
Website	https://www.danaher.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	28.02x
Average P/E ratio (10Y)	34.56x
Average P/E ratio (3Y)	40.42x
Average P/E ratio (5Y)	36.35x
Earnings yield	2.61%
EV/Earnings	43.27x
EV/EBIT	33.31x
EV/EBITDA	22.7x
EV/FCF	32.72x
EV/Sales	7.32x
FCF / EV yield	3.06%
FCF yield	3.46%
Forward EV/Sales	6.72x
Forward P/E	25.73x
Forward P/S	5.92x
Graham number	102.31921
Graham upside	-56.45%
Industry forward P/E	30.92x
Industry P/E	50.57x
Lynch fair value	$30.52
Lynch upside	-87.01%
P/(FCF - SBC) ratio	30.62x
P/(OCF - SBC) ratio	25.31x
P/B ratio	3.04x
P/E ratio	38.28x
P/FCF ratio	28.86x
P/OCF ratio	24.1x
P/S ratio	6.46x
PEG ratio	2.86x
Price/EBITDA ratio	20.02x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	21.97%
EBITDA margin	32.24%
Effective tax rate	10.98%
FCF margin	22.36%
Gross margin	59.36%
Operating margin	21.97%
Pretax margin	18.81%
Profit margin	16.91%
Profit per employee	$72,183
Profitable quarters	98
Profitable years	33
Revenue per employee	$426,800
ROA	4.06%
ROA (5Y)	4.66%
ROCE	6.68%
ROE	8.19%
ROE (5Y)	9.78%
ROIC	6.6%
ROIC (5Y)	8.05%
SBC / revenue	1.28%
Tax / revenue	2.07%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.42%
EPS growth (Q)	37.77%
EPS growth (QoQ)	42.25%
EPS growth 10Y	5.5%
EPS growth 3Y	-8.35%
EPS growth 5Y	-4.99%
EPS growth quarters	5
EPS growth years	0
FCF growth	14.15%
FCF growth 3Y	-5.76%
FCF growth 5Y	-4.09%
Gross profit growth	5.11%
Gross profit growth (Q)	12.77%
Gross profit growth 3Y	6.93%
Gross profit growth 5Y	-2.4%
Net income growth	23.64%
Net income growth (Q)	36.01%
Net income growth (QoQ)	41.95%
Net income growth 3Y	-9.66%
Net income growth 5Y	-5.42%
Net income growth quarters	5
Net income growth years	0
OCF growth	8.56%
OCF growth 10Y	5.27%
OCF growth 3Y	-5.34%
OCF growth 5Y	-3.62%
Operating income growth	7.1%
Operating income growth (Q)	10.27%
Operating income growth 3Y	3.87%
Operating income growth 5Y	-6.08%
Revenue growth	5.52%
Revenue growth (Q)	8.28%
Revenue growth (QoQ)	4.61%
Revenue growth 10Y	4.42%
Revenue growth 3Y	6.79%
Revenue growth 5Y	-1.82%
Revenue growth quarters	6
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.1B
Depreciation and amortization	$2.6B
EBIT	$5.6B
EBITDA	$8.3B
EPS	$6.10
FCF per share	$8.14
Financing cash flow	$8.4B
Free cash flow	$5.7B
Free cash flow minus SBC	$5.4B
Gross profit	$15.2B
Income taxes	$529M
Investing cash flow	$-11.1B
Net borrowing	$10.3B
Net cash flow	$4.2B
Net income	$4.3B
Operating cash flow minus SBC	$6.5B
Operating income	$5.6B
Revenue	$25.6B
Stock-based compensation	$329M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.47
Book value per share	$76.23
Debt / EBITDA	3.24
Debt / equity	0.52
Debt / FCF	4.85
Goodwill	$47.3B
Interest coverage	15.63
Long-term assets	$78.5B
Long-term liabilities	$30.6B
Net cash (debt)	$-22.1B
Net cash / market cap	-13.37%
Net debt / EBITDA	2.68
Net debt / equity	0.41
Net debt / FCF	3.86
Piotroski F-Score	5
Property, plant and equipment	$7B
Shareholders' equity	$53.6B
Tangible book value	$-14.7B
Tangible book value per share	$-20.96
Total assets	$93.3B
Total cash	$5.7B
Total debt	$27.8B
Total liabilities	$39.6B
WACC	7.56%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.3
Current assets	$14.8B
Current liabilities	$9.1B
Current ratio	1.63
Inventory turnover	3.58
Net working capital	$2.1B
Quick ratio	1.19
Working capital	$5.7B
Working capital turnover	5.68

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.6%
Dividend growth	23.58%
Dividend growth (10Y)	10.11%
Dividend growth (3Y)	12.77%
Dividend growth (5Y)	13.42%
Dividend growth years	8
Dividend payment date	2026-10-30
Dividend payment years	34
Dividend payout frequency	Quarterly
Dividend per share	$1.60
Dividend yield	0.68%
Ex-dividend date	2026-09-30
FCF payout ratio	18.67%
Last dividend	$0.40
Payout ratio	24.9%
Shareholder yield	2.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	198.88%
10Y return CAGR	13.51%
10Y total return	254.91%
150-day SMA	$197.53
15Y price change	369.63%
15Y return CAGR	14.38%
15Y total return	650.05%
1D price change	0.72%
1M price change	4.29%
1M total return	4.47%
1W price change	4.4%
1W total return	4.4%
1Y price change	5.93%
1Y return CAGR	6.71%
1Y total return	6.71%
20-day SMA	$224.48
200-day SMA	$201.13
20Y price change	566.22%
20Y return CAGR	12.6%
20Y total return	973.29%
3M price change	19.14%
3M total return	19.35%
3Y price change	24.61%
3Y return CAGR	8.24%
3Y total return	26.82%
50-day SMA	$218.02
50-day SMA vs 200-day SMA	50over200
52-week high	$242.80
52-week high date	2026-01-22
52-week low	$160.93
52-week low date	2026-05-15
5Y price change	-23.3%
5Y return CAGR	-2.36%
5Y total return	-11.24%
6M price change	29.62%
6M total return	30.11%
All-time high	$333.96
All-time high date	2021-09-10
All-time low	$0.00
All-time low date	1977-06-17
Average true range (ATR)	$6.67
Average volume	4.5M
Beta (1Y)	0.41
Beta (2Y)	0.84
Beta (5Y)	0.8
Change from 52-week high	-3.76%
Change from 52-week low	45.19%
Change from all-time high	-29.9%
Change from all-time low	11,705,400%
Change from open	1.22%
Day's gap	-0.5%
Dollar volume	$636.9M
High price	$237.91
Low price	$230.85
Monthly RSI	56.98
Open price	$230.85
Position in 52-week range	39.8%
Premarket change	-0.43%
Premarket close	$232.00
Premarket price	$231.00
Premarket volume	1.9K
Previous close	$232.00
Price vs 150-day SMA	18.52%
Price vs 20-day SMA	4.29%
Price vs 200-day SMA	16.4%
Price vs 50-day SMA	7.38%
Relative volume	0.6
RSI	62.57
Sharpe ratio	0.23
Sharpe ratio (3Y)	0.19
Sharpe ratio (5Y)	-0.09
Sortino ratio	0.52
Sortino ratio (3Y)	0.47
Sortino ratio (5Y)	0.06
Volume	2.7M
Weekly RSI	62.97
YTD price change	2.27%
YTD total return	2.88%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	626.3M
Float percentage	89.03%
Shares change (QoQ)	-0.11%
Shares change (YoY)	-1.6%
Shares held by insiders	10.86%
Shares held by institutions	83.38%
Shares outstanding	703.5M
Short % of float	1.43%
Short % of shares	1.27%
Short ratio	2.2 days

Deeper analysis on DHR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this DHR report

What is the latest published DHR stock rating?

Danaher Corporation is shown with Reduce in the latest published report, analyzed 2026-09-25. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DHR analysis?

The full latest published report, analyzed 2026-09-25, lives at /stocks/DHR/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for DHR?

The latest published report analyzed 2026-09-25 gives DHR a fair value of USD 187 and a potential value of USD 206. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the DHR page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-25). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReduceDHR · Fair value $187-16.7%

Read full analysis →

Danaher Corporation (DHR)

Our latest published analysis: DHR rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · DHR

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All DHR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DHR

Frequently asked questions

Derecelendirme geçmişi

Category	Score	Reading
Valuation	3.0
Management	8.5
Balance Sheet	7.0
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	6.5
Competitive Moat	9.0
Earnings Quality	9.0
Capital Efficiency	3.5